Advanced Biliary Tract CancerPhase 2BTC-BGBNCT04727996
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
A Phase 2 study testing Sitravatinib and Tislelizumab in people with Advanced Biliary Tract Cancer, run by Seoul National University Hospital at 1 site in South Korea.
Trial summary
This is open-label, phase II study enrolling advanced BTC patients who have failed to 1st-line chemotherapy. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Advanced Biliary Tract Cancer
- What is being tested?
- Sitravatinib and Tislelizumab
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 43 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Nov 2020to 31 Dec 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Written informed consent and any locally-required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations 2. Age≥ 20 years at time of study entry 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 4. Life expectancy of ≥ 16weeks 5. Histologically proven BTC, including intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer, ampulla of vater cancer 6. Unresectable or recurrent 7. Failed to 1st-line chemotherapy for their advanced BTC, but no more than 2 lines of prior chemotherapy regimen 8. At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (magnetic resonance imaging [MRI] where CT is contraindicated) and is suitable for repeated assessment as per RECIST 1.1.
- 9. Body weight >30kg 10. Adequate normal organ and marrow function measured within 28 days prior to administration of study treatment as defined below:
- Haemoglobin ≥9.0 g/dL
- Absolute neutrophil count (ANC) ≥ 1.5 x 10 9/L
- Platelet count ≥ 75 x 10 9/L
- Serum creatinine ≤ 1.5 x upper limit of normal (ULN), or estimated glomerular filtration rate ≥ 60 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation
Show all 11Show fewer
- AST and ALT ≤ 3.0 x ULN, or AST and ALT ≤ 5.0 x ULN for patients with documented liver metastases
- Serum total bilirubin ≤ 1.5 x ULN (total bilirubin must be < 3 x ULN for patients with Gilberts syndrome)
- International normalized ratio (INR) ≤ 1.5 or prothrombin time ≤ 1.5 x ULN
- Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN
- 11. Patients with inactive/asymptomatic carrier, chronic, or active hepatitis B virus (HBV) must have HBV deoxyribonucleic acid (DNA) < 500 IU/mL (or 2500 copies/mL) at Screening 12. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and ≥ 120 days after the last dose of study drugs and have a negative serum pregnancy test ≤ 7 days of first dose of study drugs 13. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of study drugs
Who cannot join
- 1. Unacceptable toxicity on prior anti-PD-1/PD-L1 treatment, defined as follows:
- ≥ Grade 3 AE related to anti-PD-1/PD-L1 treatment that did not respond to standard therapy and warranted treatment discontinuation.
- ≥ Grade 2 irAE(immune-related adverse event) associated with anti-PD-1/PD-L1 unless the AE(adverse event) resolved or was well controlled by withholding the anti-PD-1/PD-L1 and/or treatment with steroids, with the exception of prior colitis, encephalitis, myocarditis, hepatitis, uveitis and pneumonitis, which are exclusionary.
- Central nervous system or ocular AE of any grade related to anti-PD-1/PD-L1 Note: Patients with a prior endocrine AE are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.
- 2. Active leptomeningeal disease or uncontrolled, untreated brain metastasis
- Patients with a history of treated and, at the time of screening, asymptomatic CNS metastases are eligible, provided they meet all the following:
Show all 40Show fewer
- <!-- -->
- Brain imaging at screening shows no evidence of interim progression
- All brain metastases with supratentorial location
- No ongoing requirement for corticosteroids as therapy for CNS disease; anticonvulsants at a stable dose allowed
- No stereotactic radiation or whole-brain radiation within 14 days prior to first dose of study drug(s)
- Patients with new asymptomatic central nervous system metastases detected at the screening scan must receive radiation therapy and/or surgery for central nervous system metastases.
- Following treatment, these patients may then be eligible, provided all other criteria, including those for patients with a history of brain metastases, are met.
- 3. Active autoimmune diseases or history of autoimmune diseases that may relapse
- Note: Patients with the following diseases are not excluded and may proceed to further screening:
- Controlled Type I diabetes
- Hypothyroidism (provided it is managed with hormone replacement therapy only)
- Controlled celiac disease
- Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia)
- Any other disease that is not expected to recur in the absence of external triggering factors 4. Any active malignancy ≤ 2 years before first dose of study drugs except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast) 5. Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before first dose of study drugs
- Note: Patients who are currently or have previously been on any of the following steroid regimens are not excluded:
- <!-- -->
- Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent)
- Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption
- Short course (≤ 7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a non-autoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen) 6. Uncontrolled diabetes or > Grade 1 laboratory test abnormalities in potassium, sodium, or corrected calcium despite standard medical management or ≥ Grade 3 hypoalbuminemia ≤ 14 days before first dose of study drugs 7. History of interstitial lung disease, noninfectious pneumonitis or uncontrolled diseases, including pulmonary fibrosis, acute lung diseases, etc.
- 8. Severe chronic or active infections (including tuberculosis infection, etc.) requiring systemic antibacterial, antifungal or antiviral therapy, within 14 days prior to first dose of study drugs 9. Known history of HIV infection 10. Active hepatitis C infection (defined by a detectable HCV RNA). 11. Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drugs 12. Prior allogeneic stem cell transplantation or organ transplantation 13. Any of the following cardiovascular risk criteria:
- <!-- -->
- Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤ 28 days before first dose of study drugs
- Symptomatic pulmonary embolism ≤ 28 days before first dose of study drugs
- Any history of acute myocardial infarction ≤ 6 months before first dose of study drugs
- Any history of heart failure meeting New York Heart Association Classification III or IV ≤ 6 months before first dose of study drugs
- Any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before first dose of study drugs
- Any history of cerebrovascular accident ≤ 6 months before first dose of study drugs
- QTc interval (corrected by Fridericia's method) > 450 msec Note: If QTc interval is > 450 msec on initial electrocardiogram (ECG), a follow up ECG will be performed to confirm result
- Cardiac left ventricular ejection fraction ≤ 40% or lower limit of normal as assessed by echocardiography. The same modality used at baseline must be applied for subsequent evaluations.
- Any episode of syncope or seizure ≤ 28 days before first dose of study drugs 14. Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) 15. Hypersensitivity to tislelizumab or sitravatinib, to any ingredient in the formulation, or to any component of the container 16. Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic INR monitoring within 6 months before first dose of study drugs 17. Any systemic chemotherapy within 28 days of the first dose of study drugs or immunotherapy (eg, interleukin, interferon, thymoxin, etc.), hormone therapy, targeted therapy, or any investigational therapies within 14 days or 5 half-lives (whichever is shorter) of first dose of study drugs 18. Any herbal medicine used to control cancer within 14 days of first dose of study drugs 19. Toxicities (as a result of prior anticancer therapy) that have not improved to baseline or stabilized, except for AEs not considered a likely safety risk (eg, alopecia, neuropathy, and specific laboratory abnormalities) 20. Administration of live vaccine ≤ 4 weeks prior to first dose of study drugs Note: Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed.
- 21. Underlying medical conditions or alcohol or drug abuse or dependence that will be unfavorable for the administration of study drugs or affect the explanation of drug toxicity or AEs; or expected insufficient compliance during the study according to investigator's judgement 22. Participation in another clinical study, unless it is an observational (non interventional) clinical study or during the follow-up period of an interventional study 23. Inability to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction 24. Spinal cord compression in one or more of the following criteria
- <!-- -->
- Not definitively treated with surgery and/or radiation
- Treated but without evidence that disease has been clinically stable for > 2 weeks prior to first dose of study drugs 25. Pregnant or breastfeeding woman 26. Regardless of the severity, patients with any signs or medical history of bleeding; within 4 weeks prior to allocation, patients with any bleeding events ≥ CTCAE level 3, unhealed wounds, ulcers or fractures 27. Patients with artery/venous thrombotic occurred within 6 months before allocation, such as cerebrovascular accident (including temporary ischemic attack), deep vein thrombosis and pulmonary embolism
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Who Have Failed to At Least 1 Prior Systemic Treatment
This is open-label, phase II study enrolling advanced BTC patients who have failed to 1st-line chemotherapy.
Read the detailed description
<Study Objectives>
Primary Objectives:
To characterize the efficacy of Sitravatinib and Tislelizumab combination in biliary tract cancer patients who have failed to 1st-line chemotherapy but no more than 2 lines of prior chemotherapy regimen
Secondary Objectives:
To see the safety of Sitravatinib and Tislelizumab combination in biliary tract cancer patients who have failed to 1st-line chemotherapy
<Rationale> sitravatinib and tislelizumab may elicit greater antitumor activity, as sitravatinib is predicted to enhance several steps in the cancer immunity Cycle that may augment the efficacy of tislelizumab. First, the antitumor activity of sitravatinib may promote the release of tumor antigens. Second, inhibition of the split kinase receptors VEGFR-2 and KIT may decrease the number of Tregs and MDSCs, thus promoting the expansion and migration of antitumor cytotoxic T cells, and their infiltration into tumor tissue. Third, sitravatinib may reverse the immunosuppressive effects within the tumor microenvironment that are mediated by the TAM receptors through inhibition of MERTK, resulting in an increased number of M1- versus M2-polarized macrophages and release of IL 12, IL-6, and TNF. These downstream effects enhance CD8+ T-cell activation, and through the inhibition of AXL, promote increased antigen presentation through termination of the Toll-like receptor dependent inflammatory response in dendritic cells.
In biliary tract cancer, this sitravatinib and tislelizumab combination has not been tested so far. In this protocol, we will test sitravatinib and tislelizumab combination in advanced biliary tract cancer.
<hypothesis> Selective receptor tyrosine kinases inhibit key molecular and cellular pathways strongly implicated in checkpoint inhibitor resistance and therefore represent reasonable strategies to enhance or restore antitumor immunity when combined with anti-PD-1 or anti-PD-L1 monoclonal antibodies.
<Study design> This is open-label, phase II study enrolling advanced BTC patients who have failed to 1st-line chemotherapy.
All patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
- Conditions
- Advanced Biliary Tract Cancer
- Being tested
- Sitravatinib, Tislelizumab
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SitravatinibDrug
Also called MGCD516
120 mg will be administered orally once daily
TislelizumabDrug
Also called BGB-A317
200 mg will be administered intravenously (IV) once every 3 weeks
| Study group | Role | What they receive |
|---|---|---|
| Sitravatinib/Tislelizumab | Experimental | All patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent. Receives: Drug: Sitravatinib; Drug: Tislelizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease control rate
To assess the efficacy of Sitravatinib and Tislelizumab combination on DCR (disease control rate) in biliary tract cancer patients who have failed to 1st-line chemotherapy
Measured: every 6weeks
Secondary outcomes (3)
overall response rate
Partial response and complete response
Measured: every 6weeks
progression-free survival
Progression-free survival was defined as the duration between beginning of treatment and disease progression, any cause of death before disease progression, or the last follow-up.The event was defined as disease progression and any cause of death.
Measured: every 6weeks
overall survival
Overall survival was measured from the randomization to the last follow-up or any cause of death. The event was defined as any cause of death.
Measured: every 3months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2021
- Study start1 Nov 2020
- Primary completion31 Jul 2023
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Advanced Biliary Tract CancerStudies of the same condition, open and under way.
- More trials run by Seoul National University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 43 participants (actual)
Sponsor and investigators
- Lead sponsor
- Seoul National University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- BeiGene
- Responsible party
- Principal investigator, Do-Youn Oh, Seoul National University Hospital
- Investigators
- Do-Youn Oh, M.D., PhD., Principal investigator, Seoul National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04727996
- Sponsor's protocol ID
- H-2005-156-1126
- Acronym
- BTC-BGB
- Status last verified
- Apr 2024
- First submitted
- 23 Jan 2021
- Last updated
- 19 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Yoon J, Lee CK, Kim JW, Kang B, Park SJ, Kim JW, Chon HJ, Choi HJ, Lee MA, Kim TY, Oh DY. Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer. J Hepatol. 2026 Apr;84(4):766-775. doi: 10.1016/j.jhep.2025.10.032. Epub 2025 Nov 24.
PubMed 41297674
Study at a glance
From the registry record, last updated by the sponsor on 19 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Who Have Failed to At Least 1 Prior Systemic Treatment
- ClinicalTrials.gov ID
- NCT04727996
- Acronym / sponsor ID
- BTC-BGB / H-2005-156-1126
- Conditions
- Advanced Biliary Tract Cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 43 participants (actual)
- Lead sponsor
- Seoul National University HospitalUniversity, hospital or other
- Collaborators
- BeiGene
- Study start
- 1 Nov 2020 (actual)
- Primary completion
- 31 Jul 2023 (actual)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 27 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is open-label, phase II study enrolling advanced BTC patients who have failed to 1st-line chemotherapy.
Detailed description
<Study Objectives>
Primary Objectives:
To characterize the efficacy of Sitravatinib and Tislelizumab combination in biliary tract cancer patients who have failed to 1st-line chemotherapy but no more than 2 lines of prior chemotherapy regimen
Secondary Objectives:
To see the safety of Sitravatinib and Tislelizumab combination in biliary tract cancer patients who have failed to 1st-line chemotherapy
<Rationale> sitravatinib and tislelizumab may elicit greater antitumor activity, as sitravatinib is predicted to enhance several steps in the cancer immunity Cycle that may augment the efficacy of tislelizumab. First, the antitumor activity of sitravatinib may promote the release of tumor antigens. Second, inhibition of the split kinase receptors VEGFR-2 and KIT may decrease the number of Tregs and MDSCs, thus promoting the expansion and migration of antitumor cytotoxic T cells, and their infiltration into tumor tissue. Third, sitravatinib may reverse the immunosuppressive effects within the tumor microenvironment that are mediated by the TAM receptors through inhibition of MERTK, resulting in an increased number of M1- versus M2-polarized macrophages and release of IL 12, IL-6, and TNF. These downstream effects enhance CD8+ T-cell activation, and through the inhibition of AXL, promote increased antigen presentation through termination of the Toll-like receptor dependent inflammatory response in dendritic cells.
In biliary tract cancer, this sitravatinib and tislelizumab combination has not been tested so far. In this protocol, we will test sitravatinib and tislelizumab combination in advanced biliary tract cancer.
<hypothesis> Selective receptor tyrosine kinases inhibit key molecular and cellular pathways strongly implicated in checkpoint inhibitor resistance and therefore represent reasonable strategies to enhance or restore antitumor immunity when combined with anti-PD-1 or anti-PD-L1 monoclonal antibodies.
<Study design> This is open-label, phase II study enrolling advanced BTC patients who have failed to 1st-line chemotherapy.
All patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Sitravatinib/Tislelizumab | Experimental | Drug: Sitravatinib, Drug: TislelizumabAll patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent. |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- 1. Written informed consent and any locally-required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations 2. Age≥ 20 years at time of study entry 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 4. Life expectancy of ≥ 16weeks 5. Histologically proven BTC, including intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer, ampulla of vater cancer 6. Unresectable or recurrent 7. Failed to 1st-line chemotherapy for their advanced BTC, but no more than 2 lines of prior chemotherapy regimen 8. At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (magnetic resonance imaging [MRI] where CT is contraindicated) and is suitable for repeated assessment as per RECIST 1.1.
- 9. Body weight >30kg 10. Adequate normal organ and marrow function measured within 28 days prior to administration of study treatment as defined below:
- 11. Patients with inactive/asymptomatic carrier, chronic, or active hepatitis B virus (HBV) must have HBV deoxyribonucleic acid (DNA) < 500 IU/mL (or 2500 copies/mL) at Screening 12. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and ≥ 120 days after the last dose of study drugs and have a negative serum pregnancy test ≤ 7 days of first dose of study drugs 13. Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of study drugs
Key exclusion criteria (40 listed)
- 1. Unacceptable toxicity on prior anti-PD-1/PD-L1 treatment, defined as follows:
- 2. Active leptomeningeal disease or uncontrolled, untreated brain metastasis
- <!-- -->
- 3. Active autoimmune diseases or history of autoimmune diseases that may relapse
- Note: Patients with the following diseases are not excluded and may proceed to further screening:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SitravatinibAlso: MGCD516120 mg will be administered orally once daily | Drug | Sitravatinib/Tislelizumab |
| TislelizumabAlso: BGB-A317200 mg will be administered intravenously (IV) once every 3 weeks | Drug | Sitravatinib/Tislelizumab |
Primary outcome
Disease control rate
Time frame: every 6weeks
To assess the efficacy of Sitravatinib and Tislelizumab combination on DCR (disease control rate) in biliary tract cancer patients who have failed to 1st-line chemotherapy
3 secondary outcomes
overall response rate
Time frame: every 6weeks
progression-free survival
Time frame: every 6weeks
overall survival
Time frame: every 3months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Apr 2024.
- Derived from this study: PubMed 41297674Yoon J, Lee CK, Kim JW, Kang B, Park SJ, Kim JW, Chon HJ, Choi HJ, Lee MA, Kim TY, Oh DY. Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer. J Hepatol. 2026 Apr;84(4):766-775. doi: 10.1016/j.jhep.2025.10.032. Epub 2025 Nov 24.
- Individual participant dataSharing planned: No
Related trials for Advanced Biliary Tract Cancer
Active, not recruitingPhase 2/3
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract Cancer, Cholangiocarcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Active, not recruitingPhase 2
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Pancreatic Cancer, Hepatocellular Cancer
RecruitingPhase 2
Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Colon and Rectal Cancer
RecruitingPhase 2
MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Do-Youn Oh, M.D., PhD. principal investigator
Seoul National University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Sitravatinib and Tislelizumab in people with Advanced Biliary Tract Cancer, run by Seoul National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 40 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease control rate (time frame: every 6weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04727996, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2024; AzTrials last refreshed its copy on 8 Nov 2026.